Advertisement

Topics

Genentech gets FDA priority review for Zelboraf in Erdheim-Chester Disease

05:53 EDT 8 Aug 2017 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation.

Original Article: Genentech gets FDA priority review for Zelboraf in Erdheim-Chester Disease

NEXT ARTICLE

More From BioPortfolio on "Genentech gets FDA priority review for Zelboraf in Erdheim-Chester Disease"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...